• SPX
  • $5,444.40
  • -0.49 %
  • -$26.65
  • DJI
  • $40,470.62
  • -0.88 %
  • -$358.97
  • N225
  • $36,159.16
  • -0.16 %
  • -$56.59
  • FTSE
  • $8,205.98
  • -0.78 %
  • -$64.86
  • IXIC
  • $16,832.87
  • -0.31 %
  • -$51.74
Otonomy, Inc. (OTIC) Stock Price, News & Analysis

Otonomy, Inc. (OTIC) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$0.08
Day's range
$0.08
50-day range
$0.0075
Day's range
$0.123
  • Country: US
  • ISIN: US68906L1052
52 wk range
$0.08
Day's range
$0.08
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -17.01
  • Piotroski Score 2.00
  • Grade N/A
  • Symbol (OTIC)
  • Company Otonomy, Inc.
  • Price $0.08
  • Changes Percentage (0%)
  • Change $0.08
  • Day Low $0.08
  • Day High $0.08
  • Year High $0.08

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

  • Last Earnings N/A
  • Ex-Dividend for 5/16 Dividend 04/11/2023
  • Dividend Payable N/A
  • Today N/A
  • Next Earnings (Estimated) 07/24/2023
  • Fiscal Year End N/A

  • Average Stock Price Target $6.00
  • High Stock Price Target $6.00
  • Low Stock Price Target $6.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.06
  • Trailing P/E Ratio -0.14166666666667
  • Forward P/E Ratio -0.14166666666667
  • P/E Growth -0.14166666666667
  • Net Income $-50,325,000

Income Statement

Quarterly

Annual

Latest News of OTIC

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.